| Abstrakt: |
Objective: Temperature‐controlled radiofrequency neurolysis of the posterior nasal nerve (PNN) has been approved for use since 2020. This review synthesized the published data to assess its efficacy for treatment of chronic rhinitis. Data Sources: Pubmed/Medline, Embase, Scopus, Web of Science. Review Methods: A systematic search was conducted with no restrictions on publication years in April 2023. RCTs and prospective investigations that reported the reflective Total Nasal Symptom Score (rTNSS) outcome of radiofrequency neurolysis as a single procedure in chronic rhinitis patients were included. Pooled estimates for change in rTNSS from baseline at 3 months and responder rates (≥30% reduction in baseline rTNSS) at 3 and 6 months were obtained. Other outcomes, such as postnasal drip and cough scores, quality of life (QoL) measures, and adverse events were included for qualitative review. Results: Five studies were included in the systematic review, of which four were included in the meta‐analysis. A total of 284 participants underwent treatment. The pooled change in rTNSS score at 3 months was −4.28 (95% CI, −5.10 to −3.46). The pooled responder rate at 3 months was 77.11% (95% CI, 68.21%–86.01%) and at 6 months 80.80% (95% CI, 70.85%–90.76%). Postnasal drip and cough scores and QoL also improved significantly at follow up. A total of 36 adverse events were reported in 21 (7.4%) patients. Conclusions: The findings from this review suggest that temperature‐controlled radiofrequency neurolysis of the PNN is effective at treating chronic rhinitis symptoms and that it has an overall favorable safety profile. Laryngoscope, 134:507–516, 2024 [ABSTRACT FROM AUTHOR] |
Plný text